Denali Therapeutics Inc (DNLI) Short Interest Up 1,101.8% in December

Denali Therapeutics Inc (NASDAQ:DNLI) saw a significant growth in short interest in December. As of December 29th, there was short interest totalling 2,291,611 shares, a growth of 1,101.8% from the December 15th total of 190,677 shares. Currently, 4.5% of the company’s shares are sold short. Based on an average daily trading volume, of 434,780 shares, the days-to-cover ratio is currently 5.3 days.

Shares of Denali Therapeutics (DNLI) opened at $16.53 on Friday. The stock has a market cap of $1,450.00 and a P/E ratio of -16.05. Denali Therapeutics has a 52-week low of $14.72 and a 52-week high of $22.95.

In other news, major shareholder Douglas K. Bratton acquired 275,000 shares of Denali Therapeutics stock in a transaction on Tuesday, December 12th. The stock was bought at an average cost of $18.00 per share, with a total value of $4,950,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

DNLI has been the subject of a number of analyst reports. Goldman Sachs Group initiated coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set a “neutral” rating for the company. JPMorgan Chase & Co. began coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “overweight” rating and a $24.00 price objective for the company. Morgan Stanley began coverage on shares of Denali Therapeutics in a research report on Tuesday, January 2nd. They issued an “overweight” rating and a $25.00 price target for the company. Finally, Evercore ISI began coverage on shares of Denali Therapeutics in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $23.00 price target for the company.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/12/denali-therapeutics-inc-dnli-short-interest-up-1101-8-in-december.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply